In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

AbbVie Inc.’s stock rose 5% early Friday to lead S&P 500 gainers premarket, after the drug company beat fourth-quarter ...

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...

AbbVie stock popped Wednesday after the pharma behemoth's new king in immunology finally outpaced its grandfather drug, ...

AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term ...

Quarterly sales of Humira declined 49% to $1.68 billion, a steeper fall than the $1.99 billion analysts expected, according to data compiled by LSEG. Once the world's best-selling drug ...

AbbVie's success with Humira is a textbook example. Humira (adalimumab) is an immunosuppressant drug used to treat several autoimmune diseases, in which a patient's immune system attacks healthy ...

Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. In a unique challenge to drug makers, the Dutch Pharmaceutical ...

The injection is given in the thigh or abdomen. The dosage is based on your medical condition and response to treatment. Children's dosage is also based on weight. If you are using this medication ...

As pharmaphorum recently reported, the entrance of biosimilars to Humira is a significant event for a number of reasons, not least because the drug is the top-selling pharmaceutical product of all ...

Yesterday, Amgen announced that it would launch the U.S.’s first marketed Humira-referenced biosimilar ... Rebates are payments made by drug manufacturers to PBMs and insurers in exchange ...

Humira is the company's blockbuster immunology drug, which has faced competition from biosimilars since 2023. North Chicago, Ill.-based AbbVie (ABBV) had a loss per share of 2 cents, due to an ...